Minocyn
Minocyn Brand names, Minocyn Analogs
Minocyn Brand Names Mixture
- No information avaliable
Minocyn Chemical_Formula
C23H27N3O7
Minocyn RX_link
http://www.rxlist.com/cgi/generic/minocycline.htm
Minocyn fda sheet
Minocyn msds (material safety sheet)
Minocyn Synthesis Reference
Boothe, Petisi, U.S. Pat. 3,148,212 (1964)
Minocyn Molecular Weight
457.477 g/mol
Minocyn Melting Point
No information avaliable
Minocyn H2O Solubility
52 mg/mL
Minocyn State
Solid
Minocyn LogP
0.092
Minocyn Dosage Forms
Capsules; Subgingival (sustained-release); IV injection
Minocyn Indication
For the treatment of infections caused by susceptible strains of microorganisms, such as Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsial pox and tick fevers caused by Rickettsiae, upper respiratory tract infections caused by Streptococcus pneumoniae and for the treatment of asymptomatic carriers of Neisseria meningitidis.
Minocyn Pharmacology
Minocycline, the most lipid soluble and most active tetracycline antibiotic, is, like doxycycline, a long-acting tetracycline. Minocycline's effects are related to the inhibition of protein synthesis. Although minocycline's broader spectrum of activity, compared to other members of the group, includes activity against Neisseria meningitidis, its use as a prophylaxis is no longer recomended because of side effects (dizziness and vertigo). Current research is examining the possible neuroprotective effects of minocycline against progression of Huntington's Disease, an inherited neurodegenerative disorder. The neuroprotective action of minocycline may include its inhibitory effect on 5-lipoxygenase, an inflammatory enzyme associated with brain aging.
Minocyn Absorption
Rapidly absorbed from the gastrointestinal tract and absorption is not significantly impaired by ingestion of food or milk. Oral bioavailability is 100%.
Minocyn side effects and Toxicity
Minocycline has been observed to cause a dark discoloration of the thyroid in experimental animals (rats, minipigs, dogs and monkeys). In the rat, chronic treatment with minocycline has resulted in goiter accompanied by elevated radioactive iodine uptake and evidence of thyroid tumor production. Minocycline has also been found to produce thyroid hyperplasia in rats and dogs. LD50=2380 mg/kg (rat, oral), LD50=3600 mg/kg (mouse, oral)
Minocyn Patient Information
Minocyn Organisms Affected
Enteric bacteria and other eubacteria
